3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
11
Gemcitabine
10
Doxorubicin
10
Cyclophosphamide
9
Specimen Handling
8
Nivolumab
8
Ibandronic Acid
8
pazopanib
7
Radiosurgery
6
Magnetic Resonance Spectroscopy
6
Imatinib Mesylate
6
Biopsy
6
Bevacizumab
6
Irinotecan
5
regorafenib
4
Zoledronic Acid
4
Ipilimumab
4
Ifosfamide
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
sargramostim
3
conatumumab
3
cemiplimab
3
Sunitinib
3
Radiation
3
Paclitaxel
3
Leucovorin
3
Cryosurgery
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
tinostamustine
×
Sarcoma
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts